Apixaban with the trade name Eliquis is an orally active, reversible, selective factor Xa inhibitor. Specialist indicates this medication for the treatment of venous thromboembolic events that are taken by mouth.
This anticoagulant prevents thrombin generation and thrombus formation; it decreases the conversion of prothrombin to thrombin. After approval in 2012, Pfizer and Bristol-Myers Squibb developed Apixaban in a joint venture. Apixaban is the third novel oral anticoagulant approved in the U.S. for the management of thromboembolic disease.
Pembrolizumab that formerly named MK-3475 and Lambrolizumab with the trade name Keytruda is a humanized antibody used in cancer immunotherapy. It was approved for the treatment of melanoma, certain subsets of colorectal cancer, head and neck cancers, metastatic bladder cancer, certain types of lung cancer, and a few other malignancies and has shown effectiveness with many mesothelioma patients. Fatigue and Cough are the most common Keytruda side effects.
Aflibercept with the trade name Eylea is made from a human antibody fragment. Regeneron Pharmaceuticals invented this biopharmaceutical drug for the treatment of wet macular degeneration as Eylea injection and also for metastatic colorectal cancer under the trade name Zaltrap.